Venu Holding Corporation Partners with Sands Investment Group for Nationwide NNN Luxe FireSuite Real Estate Opportunity
SIG is nationally recognized for its innovative approach to commercial real estate solutions. Through this new partnership, qualified investors can now participate in VENU's income-producing long-term asset under a triple net lease structure, offering a projected 11-12% cap rate. Like a traditional NNN, this provides a predictable return while shifting the responsibility for property expenses (such as taxes, insurance, and maintenance) onto the tenant, making it attractive to a diverse investment portfolio.
'We are thrilled to have SIG along with us on this journey.' Says J.W. Roth Founder, Chairman and CEO of VENU. 'Their commitment to world- class client service aligns perfectly with our vision for the future of the entertainment industry. This partnership represents a significant expansion, broadening our reach once again to include a wider network of real estate-focused investors all across the country.'
'What VENU is doing is truly next level.' Says Clifton McCrory, Vice President of Sands Investment Group 'Live music is thriving, and they're leading the charge into a whole new era of opportunity. We're excited to partner exclusively with them to bring NNN opportunities to SIG investors, it's an incredible way to amplify any portfolio.'
What is VENU's NNN Luxe FireSuite??
Luxe FireSuite fractional real-estate ownership investment opportunities are available at all VENU amphitheaters. The Company sets aside a select 10% of the total seating capacity (nearly 35% of the project square footage depending on the location) exclusively for the private use and enjoyment of VENU's fractional owners. Each unique suite, seating 4-10 fans based on investment level, provides unparalleled financial benefits, investment through guaranteed rents (at applicable locations), and depreciation advantages. Availability is limited—once they're gone, they're gone—making Luxe FireSuites one of VENU's most sought-after opportunities.
To find out more email clifton@sandsig.com.
About Venu Holding Corporation
Venu Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier hospitality and live music venue developer dedicated to crafting luxury, experience-driven entertainment destinations. VENU's campuses in Colorado Springs, Colorado, and Gainesville, Georgia, each feature Bourbon Brothers Smokehouse and Tavern, The Hall at Bourbon Brothers, and unique to Colorado Springs, Notes Eatery and the 8,000-seat Ford Amphitheater. Expanding with new Sunset Amphitheaters in Oklahoma and Texas, VENU's upcoming large-scale venues will host between 12,500 and 20,000 guests, continuing VENU's vision of redefining the live entertainment experience. Click here for company overview.
VENU has been recognized nationally by The Wall Street Journal, The New York Times, Denver Post, Billboard, VenuesNow, and Variety for its innovative and disruptive approach to live entertainment. Through strategic partnerships with industry leaders such as AEG Presents and NFL Hall of Famer and Founder of EIGHT Elite Light Lager, Troy Aikman, VENU continues to shape the future of the entertainment landscape. For more information, visit venu.live
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
a day ago
- Miami Herald
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: CLDI: In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Calidi's pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic sites and deliver genetic medicines to treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus to evade immune detection and circulate throughout the body. Preclinical data showcased at AACR and ASCO demonstrated that a single dose of Calidi's lead candidate, CLD-401, not only eliminated metastatic tumors but also primed immune memory, offering the potential to prevent recurrence. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The company is advancing toward IND filing in 2026, while exploring strategic pharma partnerships to support global commercialization. Calidi's capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight its strong potential to deliver value to shareholders. Dr. Steven Quay, CEO of Atossa Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Atossa's strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen - a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company's differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value. CLDI and ATOS are clients of RedChip Companies. Please read our full disclosure at About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company's proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ SOURCE: RedChip Companies, Inc.
Yahoo
a day ago
- Yahoo
SIFCO Industries, Inc. (SIF) Has Surged 67% Since May. Here Is Why
SIFCO Industries, Inc. (NYSEAMERICAN:SIF) is among the 10 Best Low Priced Defense Stocks to Buy Now. The stock has surged nearly 67% since the announcement of second-quarter and first-half results for fiscal 2025 on May 16. Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels For the quarter ended March 31, the company reported net sales of $19 million, down 3% from last year, primarily due to raw material sourcing challenges. Despite the dip, SIFCO Industries, Inc. (NYSEAMERICAN:SIF) narrowed its net loss from continuing operations to $(0.22) per diluted share from $(0.38) in Q2 2024. Total net loss also declined to $1.4 million from $1.6 million in the prior year's quarter. The company's half-yearly performance has also been impressive, with net sales growing 9% year-over-year to $39.9 million. Total net loss for the first six months of fiscal 2025 stood at $3.7 million, down from approximately $5 million during the same period last year. Moreover, SIFCO Industries, Inc. (NYSEAMERICAN:SIF)'s backlog continues to grow and was reported at $129.2 million, reflecting robust demand for the firm's products. SIFCO Industries, Inc. (NYSEAMERICAN:SIF) produces forgings and machined components for the aerospace, energy, defense, and commercial space markets. According to Insider Monkey's database for Q1 2025, 3 hedge funds held a stake in the company. While we acknowledge the potential of SIF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Aerospace Stocks to Buy Now and 13 Best Global Stocks to Buy Right Now. Disclosure: None.
Business Wire
a day ago
- Business Wire
Imperial declares third quarter 2025 dividend
CALGARY, Alberta--(BUSINESS WIRE)--Imperial Oil Limited (TSE: IMO, NYSE American: IMO) today declared a quarterly dividend of 72 cents per share on the outstanding common shares of the company, payable on October 1, 2025, to shareholders of record at the close of business on September 4, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of 72 cents per share. Imperial has a long and successful history of growth and financial stability in Canada as a leading member of the petroleum industry. The company has paid dividends every year for over a century and has increased its annual dividend payment for 30 consecutive years. Source: Imperial After more than a century, Imperial continues to be an industry leader in applying technology and innovation to responsibly develop Canada's energy resources. As Canada's largest petroleum refiner, a major producer of crude oil, a key petrochemical producer and a leading fuels marketer from coast to coast, our company remains committed to high standards across all areas of our business.
